Biohaven Rallies On Heels Of $600M Funding Agreement With Oberland
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Source: Benzinga
Biohaven's Investment Agreement: Biohaven Ltd. has entered a $600 million investment agreement with Oberland Capital Management, structured through a non-dilutive Note Purchase Agreement, which will support clinical trials and commercialization of its drug, troriluzole, pending FDA approval.
Stock Performance: Following the announcement, Biohaven shares rose by 5.85% in premarket trading, reflecting positive investor sentiment regarding the funding and potential future developments related to the treatment for spinocerebellar ataxia.
Analyst Views on PINK
Wall Street analysts forecast PINK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PINK is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 37.810
Low
Averages
High
Current: 37.810
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
